BeyondSpring price target lowered to $1.25 from $4 at Baird

Baird analyst Joel Beatty lowered the firm’s price target on BeyondSpring to $1.25 from $4 and keeps an Outperform rating on the shares. The analyst ssaid the reduction comes from removing plinabulin completely from our model, after approval was denied in China in 1Q23 and a CRL from the FDA was issued in 2021.